<DOC>
	<DOCNO>NCT03087201</DOCNO>
	<brief_summary>This multicentre , randomize , double-blind , placebo control , parallel-group , phase IIIb trial . Patients ( ≥18 year ) chronic tic disorder Tourette syndrome recruit . The objective trial demonstrate treatment cannabis extract nabiximols superior placebo reduce tic comorbidities patient Tourette syndrome chronic tic disorder .</brief_summary>
	<brief_title>CANNAbinoids Treatment TICS ( CANNA-TICS )</brief_title>
	<detailed_description />
	<mesh_term>Tourette Syndrome</mesh_term>
	<mesh_term>Tic Disorders</mesh_term>
	<mesh_term>Tics</mesh_term>
	<criteria>1 . Chronic tic disorder Tourette syndrome accord DSM5 2 . Age ≥18 year 3 . Total tic score Yale Global Tic Severity Scale ( YGTSSTTS ) &gt; 14 patient Tourette syndrome YGTSSTTS &gt; 10 patient chronic motor vocal tic ( = CTD ) 4 . Clinical Global ImpressionSeverity Score ( CGIS ) ≥ 4 5 . Medication ( stimulation parameter deep brain stimulation ) tic comorbidities must stable dose least 30 day enter study patient must consent maintain stable dose study 6 . Signed write informed consent willingness comply treatment followup procedures 7 . Patients capable understanding investigational nature , potential risk benefit clinical trial 8 . Prevention pregnancy : Women without childbearing potential defined follow : least 6 week surgical sterilization bilateral tubal ligation bilateral oophorectomy hysterectomy uterine agenesis ≥ 50 year postmenopausal state ≥ 1 year &lt; 50 year postmenopausal state ≥ 1 year urine FSH &gt; 40 IU/l urine oestrogen &lt; 30 ng/l negative oestrogen test Women childbearing potential negative ßHCG pregnancy test screen agree meet one follow criterion time screening , study period three month follow last administration study medication : correct use contraception method . The follow acceptable : hormonal contraceptive ( combined oral contraceptive oestrogenfree pill desogestrel , implant , transdermal patch , hormonal vaginal device injection prolong release ) , intrauterine device ( IUS ) barrier method , e.g . condom occlusive cap ( diaphragm cervical/vault cap ) spermicide ( foam , gel , film , cream suppository ) true abstinence ( periodic abstinence withdrawal acceptable method contraception ) sexual relationship female partner and/or sterile male partner Males surgically sterile sexually active female partner ( ) childbearing potential must agree correct use one follow contraception method time screening , study period three month follow last administration study medication : hormonal contraceptive ( combined oral contraceptive oestrogenfree pill desogestrel , implant , transdermal patch , hormonal vaginal device injection prolong release ) , intrauterine device ( IUS ) barrier method , e.g . condom occlusive cap ( diaphragm cervical/vault cap ) spermicide ( foam , gel , film , cream suppository ) 1 . Comorbid obsessivecompulsive disorder ( OCD ) , attention deficit/hyperactivity disorder ( ADHD ) , depression , anxiety disorder unstable and/or need initial adjustment therapy 2 . Ongoing behavioural treatment tic 3 . History schizophrenia , psychotic , severe personality , pervasive developmental disorder 4 . Current clinical diagnosis substance abuse dependence compulsive disorder 5 . Secondary tic disorder significant neurological disorder , opinion investigator , might interfere patient 's participation study , pose added risk patient , confound assessment patient safety 6 . Severe cardiovascular disease , hepatitis C , severe hepatic renal disorder history , opinion investigator , might interfere patient 's participation study , pose added risk patient , confound assessment patient safety 7 . Any medical condition base medical history , physical examination , vital sign measurement , opinion Investigator , might interfere patient 's participation study , pose added risk patient , confound assessment patient safety 8 . Use cannabis cannabinoidbased medicine ( CBM ) 30day period prior study entry and/or positive delta9tetrahydrocannabinol ( THC ) urine test 9 . Positive urine pregnancy test 10 . Pregnancy lactation period 11 . The subject receive investigational medication use investigational device within 30 day prior first dose study medication actively participate investigational drug device study , schedule receive investigational drug use investigational device course study . 12 . Known suspected hypersensitivity active substance excipients investigational medicinal product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic tic disorder</keyword>
	<keyword>Tourette syndrome</keyword>
</DOC>